Benchmark ceiling and cheapest lawful option

Employer will reimburse Claim Administrator for Claims submitted under the pharmacy program based on the pricing set forth in the BPA Addendum.

Recorded reference: Page 46

Published rationale. The produced text never states that plan cost on a claim cannot exceed a published benchmark or cash price. Page 46 Section 10 says the Employer reimburses at the pricing set forth in the BPA Addendum, and page 14 Section 7.2(b) says the Allowable Amount for participating pharmacies is the cost mutually agreed in the PBM Fee Schedule Addendum. Exhibit 7 defines Usual and Customary on page 49 as the cash price a pharmacy would charge including discounts, which suggests a lesser of test may exist in the addendum pricing, but the addendum is not included so the text does not show whether any ceiling applies or whether it is tested claim by claim or in aggregate. The exhibit title on page 43, Guaranteed Traditional Aggregate Pricing Arrangement, points toward aggregate rather than claim level measurement. Because the term would live in an explicitly referenced but omitted attachment, the verdict is unclear rather than missing.

The published verdict is unclear because the relevant material could not be assessed. It is not a missing provision and does not receive a zero-weight verdict.

No evidence quotation was recorded for this finding.

Recorded reference: No page reference recorded

Published rationale. I reviewed the prescription drug allowable amount provisions on Page 14, the general financial terms on Pages 21 through 25, and the pharmacy benefit management pricing provisions on Pages 43 through 49 of the document. The text contains no provision establishing a claim by claim pricing ceiling tied to transparent public cash benchmarks or the cheapest lawful option. Because the contract contains no benchmark ceiling mechanism in any channel, this rubric item is missing from the produced text.

“Not addressed” is this published review’s conclusion about the produced text, not proof that a provision is absent from every version or withheld document.

No evidence quotation was recorded for this finding.

Recorded reference: No page reference recorded

Published rationale. I reviewed the prescription drug Allowable Amount definition on page 14, the pharmacy pricing and rebate provisions on pages 27 and 28, and the whole pharmacy exhibit on pages 43 through 49. Participating pharmacy amounts and specialty drug prices are placed in the omitted PBM Fee Schedule Addendum, but the visible agreement does not state a published cash-price or other external benchmark ceiling applied claim by claim in every channel. The page 49 usual and customary cash-price definition is not an operative guarantee that the plan's claim cost is capped by that price. Because an actual claim rate is in the missing addendum, it cannot be measured here, but a benchmark-ceiling covenant is simply not addressed in the produced terms.

“Not addressed” is this published review’s conclusion about the produced text, not proof that a provision is absent from every version or withheld document.

No evidence quotation was recorded for this finding.

Recorded reference: No page reference recorded

Published rationale. I looked for a claim level ceiling in Section 7, Exhibit 2, Exhibit 3, and Exhibit 7. Allowable Amount for participating pharmacies, on Page 14, is the cost mutually agreed in the omitted PBM Fee Schedule Addendum. Non-network pharmacy allowable amount on the same page is the lesser of the pharmacy's usual charge or the participating reimbursement minus twenty percent. That is a non-network method, not a rule that plan cost can never exceed a published cash benchmark in every channel. Usual and Customary is defined on Page 49 as the cash price a network pharmacy would charge, and the produced text never applies that definition as a claim by claim ceiling on what the Employer pays. Exhibit 7 is a guaranteed traditional aggregate pricing arrangement. Aggregate guarantees, whose figures are not here, are averages, not a claim level test against a published benchmark. The model contract requires plan claim cost never to exceed a published benchmark, in any channel and for any drug, checked claim by claim. Nothing in this file states that rule, and the omitted addendum is described as agreed pricing and aggregate guarantees, not as a benchmark ceiling. This is missing, not unclear.

“Not addressed” is this published review’s conclusion about the produced text, not proof that a provision is absent from every version or withheld document.

No evidence quotation was recorded for this finding.

Recorded reference: No page reference recorded

Published rationale. The model term caps plan claim cost at a published benchmark price in every channel, tested claim by claim. I looked through the Allowable Amount definitions on pages 13 through 15, the program pricing terms in Exhibit 7 on pages 45 through 47, and the Usual and Customary definition on page 49. The closest provision is on page 14: for non-network pharmacies the allowable amount is the lesser of the pharmacy's usual charge or the participating pharmacy amount minus twenty percent, but that is a benefit basis reduction for out of network claims, not a ceiling against a public cash price benchmark across all channels. The U&C definition on page 49 defines the cash price but is never used to cap what the plan or member pays. No claim level benchmark ceiling exists anywhere in the document, so this term is simply not addressed.

“Not addressed” is this published review’s conclusion about the produced text, not proof that a provision is absent from every version or withheld document.